aTyr Pharma Announces Positive Data from Phase 1b/2a Clinical Trial Demonstrating Consistent Dose Response for ATYR1923 in Pulmonary Sarcoidosis
September 13, 2021 07:30 ET
|
aTyr Pharma, Inc.
Trial met primary endpoint, ATYR1923 was safe and well-tolerated. Efficacy observed in key endpoints including steroid reduction of 58% in the 5.0 mg/kg treatment group with 33% of patients in the...
aTyr Pharma Announces Second Quarter 2021 Results and Provides Corporate Update
August 10, 2021 16:00 ET
|
aTyr Pharma, Inc.
Data from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis expected in mid-September 2021. Company to host conference call and webcast today, August 10th, at 5:00 p.m. EDT / 2:00 p.m....
aTyr Pharma Announces Expansion of Research Collaboration with The Ohio State University
August 10, 2021 08:00 ET
|
aTyr Pharma, Inc.
Collaboration led by Dr. Elliott Crouser to explore underlying cellular mechanisms of pulmonary sarcoidosis and identify potential sarcoidosis biomarkers. SAN DIEGO, Aug. 10, 2021 (GLOBE NEWSWIRE)...
aTyr Pharma Announces Two Abstracts for ATYR1923 Accepted for Presentation at the European Respiratory Society International Congress
August 09, 2021 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma to Webcast Conference Call Reporting Second Quarter 2021 Financial Results
August 03, 2021 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Aug. 03, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Announces Grant of U.S. Patent for Use of Histidyl-tRNA Synthetase Fc Fusion Proteins for Reducing Inflammatory Response in the Lung
July 29, 2021 16:05 ET
|
aTyr Pharma, Inc.
SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Announces Last Patient Visit in Phase 1b/2a Clinical Trial of ATYR1923 in Patients with Pulmonary Sarcoidosis
July 08, 2021 08:00 ET
|
aTyr Pharma, Inc.
Results from proof-of-concept study are expected in September 2021. SAN DIEGO, July 08, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery...
aTyr Pharma to Host Virtual Key Opinion Leader Event on Current Treatment Options for Pulmonary Sarcoidosis
June 23, 2021 08:00 ET
|
aTyr Pharma, Inc.
Event will feature Dr. Daniel Culver, Director of the Interstitial Lung Disease Program at the Cleveland Clinic. Conference call and webcast scheduled for Tuesday June 29th at 5:00pm ET/2:00pm PT. ...
aTyr Pharma Announces First Quarter 2021 Results and Provides Corporate Update
May 13, 2021 16:05 ET
|
aTyr Pharma, Inc.
Data from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis expected in the third quarter. Preclinical data for IND candidate ATYR2810 showed anti-tumor effects in models of TNBC and...
aTyr Pharma and its Hong Kong Subsidiary, Pangu BioPharma, Achieve Milestones for First Year of Government Grant to Develop Bispecific Antibody Platform
May 12, 2021 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, May 12, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...